Genmab in Talks to Acquire Merus in Landmark $5.2B Biotech Deal

Danish biotechnology leader Genmab A/S (CSE: GMAB) is reportedly in advanced negotiations to acquire Merus NV (NASDAQ: MRUS), a Dutch biotech company specializing in innovative cancer therapies. According to Bloomberg, people familiar with the matter indicated that the potential deal could be announced within days.

If completed, this acquisition would mark the largest deal in Genmab’s history, underscoring the company’s commitment to strengthening its oncology pipeline. Genmab, based in Copenhagen, currently has a market capitalization of about $18.5 billion, while Merus is valued at approximately $5.2 billion on Nasdaq.

Merus has recently attracted strong interest from several major pharmaceutical companies due to the success of its experimental cancer drug, petosemtamab. In May, the company reported encouraging clinical trial data showing that petosemtamab significantly shrank tumors in patients with head-and-neck cancer. When paired with Merck’s (NYSE: MRK) blockbuster immunotherapy Keytruda, the treatment demonstrated greater effectiveness than existing standard therapies, boosting investor confidence and propelling Merus shares higher.

For Genmab, which has built a strong reputation for developing antibody-based treatments, acquiring Merus could provide a strategic edge in the competitive immuno-oncology market. The deal would expand its drug portfolio, enhance collaboration opportunities with pharmaceutical giants, and accelerate the development of next-generation therapies targeting some of the most challenging cancers.

Industry analysts note that such a move reflects a broader trend in the biotech sector, where established players are aggressively pursuing mergers and acquisitions to secure breakthrough technologies and promising drug candidates. If finalized, this transaction would not only reshape Genmab’s growth trajectory but also reinforce its position as a global oncology powerhouse.

The coming days will be crucial as discussions progress, with investors closely watching for official confirmation of what could become a transformational deal in the biotech industry.